Prevention of transmission of human T-lymphotropic virus type 1 (HTLV-1) through transfusion, by donor screening with antibody to the virus. One-year experience.
To prevent the transmission of human T-lymphotropic virus, type 1 (HTLV-1) during blood transfusion, a program was implemented to screen donors for antibodies to the virus, using a newly developed, passive agglutination (PA) method. During the period April 1986 to March 1987, 675 recipients of donor blood in whom the antibody to HTLV-1 was not present before transfusion were followed for at least 50 days after transfusion. One of these 675 seroconverted despite the transfusion of screened blood, but this seroconversion rate (0.15%) represents a marked decrease from the rate of 8.3 percent prevalent before donor screening began. The rate in the Fukuoka area of donors seropositive for anti-HTLV-1 is 5.34 percent, as detected by the PA method and 1.80 percent, as assessed by the indirect immunofluorescence (IF) technique, with PA-positive but IF-negative blood units thus accounting for 3.5 percent (5.34-1.80) of the total blood donated. The seroconversion rate among recipients transfused with blood screened by IF (at Kyushu University Hospital only) from 1981 to 1985 was 0.41 percent, which was not significantly different from the rate of 0.15 percent observed after PA screening. The discrepancy between PA and IF in the rate of seropositivity was due, in part, to the higher sensitivity of PA in detecting anti-HTLV-1. It is proposed that all donor blood in areas where HTLV-1 is endemic be screened by PA before transfusion.(ABSTRACT TRUNCATED AT 250 WORDS)
Inaba
S
S
Blood Transfusion Service, Kyushu University Hospital, Fukuoka, Japan.
Sato
H
H
Okochi
K
K
Fukada
K
K
Takakura
F
F
Tokunaga
K
K
Kiyokawa
H
H
Maeda
Y
Y
D000372:Agglutination Tests / Q000379:methods; D001782:Blood Donors; D015153:Blotting, Western; D005455:Fluorescent Antibody Technique; D015481:HTLV-I Antibodies / Q000032:analysis* / Q000096:biosynthesis; D015486:HTLV-I Antigens / Q000276:immunology*; D015490:HTLV-I Infections / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D011446:Prospective Studies; D012189:Retrospective Studies; D065227:Transfusion Reaction
D015481:HTLV-I Antibodies; D015486:HTLV-I Antigens